Table 1.
Description of Patient Characteristics, Severe Acute Respiratory Syndrome Coronavirus 2 Variant Type and Treatments, and Response to Extended Nirmatrelvir/Ritonavir
| Characteristic | Patient 1 | Patient 2 | Patient 3 | Patient 4 |
|---|---|---|---|---|
| Demographics | ||||
| Age | 79 y | 72 y | 72 y | 60 y |
| Ethnicity | Non-Hispanic | Non-Hispanic | Non-Hispanic | Non-Hispanic |
| Sex | Female | Male | Male | Female |
| Underlying condition | Follicular lymphoma | Diffuse large B-cell lymphoma | Mantle cell lymphoma | B-cell ALL |
| Duration of SARS-CoV-2 positivity | 8 mo | 1.5 mo | 3 mo | 2 mo |
| Duration of symptoms | 8 mo | 2 mo | 4 mo | 3 mo |
| SARS-CoV-2 variant type | BA.1.1 | NA | BA.5.2.1 | BF.28 |
| SARS-CoV-2 treatments (total) | ||||
| Remdesivir | Yes | Yes | Yes | Yes |
| Nirmatrelvir/ritonavir (standard course) | No | Yes | No | Yes |
| Molnupiravir | Yes | No | No | No |
| Bebtelovimab | No | No | Yes | Yes |
| SARS-CoV-2 treatments (at the time of extended nirmatrelvir/ritonavir administration) | Remdesivir | Remdesivir | Remdesivir | Remdesivir, bebtelovimab |
| Extended nirmatrelvir/ritonavir duration | 21 d | 20 d | 15 d | 21 d |
| Response to nirmatrelvir/ritonavir | Clinical, virologic | Clinical, virologic | Clinical | Clinical, radiologic |
Abbreviations: ALL, acute lymphoblastic leukemia; NA, not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.